Palliative radiotherapy with lurbinectedin in patients with extensive stage SCLC скачать в хорошем качестве

Palliative radiotherapy with lurbinectedin in patients with extensive stage SCLC

Lurbinectedin recently gained accelerated approval following the demonstration of a favorable response rate, duration of response, and toxicity profile in patients with platinum-refractory extensive-stage small cell lung cancer (ES-SCLC). Both lurbinectedin and radiotherapy induce lethal DNA damage which suggests they may be therapeutically additive or even synergistic. Neal Sean McCall, MD, Winship Cancer Institute, Emory University, Atlanta, GA, provides an overview of a Phase I study (NCT05244239) investigating whether radiotherapy can be delivered safely with concurrent, uninterrupted lurbinectedin in patients with ES-SCLC. The primary safety endpoint is grade 4 or 5 adverse events occurring within 30 days of radiotherapy or adverse event leading to prolonged delay or permanent discontinuation of lurbinectedin. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.